Structure via PubChem · Public domain (PubChem)
elvitegravir
Sign in to saveAlso known as JTK-303, 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, GS-9137, EVG, GS 9137
Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on 27 August 2012, for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On 24 September 2014, the FDA approved Elvitegravir as a single pill formulation under the trade name Vitekta. On 5 November 2015, the FDA approved the drug for use in patients affected with HIV-1 as
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 437144022
- Drug.image
- Elvitegravir structure.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of elvitegravir Below: 3D representation of an elvitegravir molecule
- Drug.image2
- Elvitegravir 3D structure.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Vitekta; Stribild (fixed-dose combination)
- Drug.licence_EU
- yes
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AJ02
- Drug.protein_bound
- 98%
- Drug.metabolism
- liver, via CYP3A
- Drug.elimination_half life
- 12.9 (8.7–13.7) hours
- Drug.excretion
- liver 93%, renal 7%
- Drug.CAS_number
- 697761-98-1
via Wikipedia infobox
Chemical data
- Formula
- C23H23ClFNO5
- Molecular weight
- 447.9 g/mol
- IUPAC name
- 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
- SMILES
- CC(C)[C@@H](CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O
- InChIKey
- JUZYLCPPVHEVSV-LJQANCHMSA-N
- XLogP
- 5.3
- Polar surface area
- 87.1 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2012
- Admin. routes
- oral
- Indications
- HIV-1 infection, viral disease, HIV infection, AIDS
via ChEMBL · EBI
Wikidata facts
- Mass
- 447.125
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₃H₂₃ClFNO₅
- isomeric SMILES
- CC(C)[C@@H](CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O
- canonical SMILES
- CC(C)C(CO)N1C=C(C(=O)C2=CC(=C(C=C21)OC)CC3=C(C(=CC=C3)Cl)F)C(=O)O
- Commons category
- Elvitegravir
- World Health Organisation international non-proprietary name
- elvitegravir
- subject has role
- antiviral drug
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- Interactions and contraindications
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- References
Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on 27 August 2012, for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On 24 September 2014, the FDA approved Elvitegravir as a single pill formulation under the trade name Vitekta. On 5 November 2015, the FDA approved the drug for use in patients affected with HIV-1 as a part of a second fixed dose combination pill known as Genvoya.
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.
Excerpted from Wikipedia’s “elvitegravir” article, available under the CC BY-SA 4.0 licence.